Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis

Journal of Rheumatology

Volumn 42, Issue 2, 2015, Pages 236-242

  Poelman, Corrie L ^a   Hummers, Laura K ^a   Wigley, Fredrick M ^a   Anderson, Cynthia ^a   Boin, Francesco ^a   Shah, Ami A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

D; I; S

Indexed keywords

ALEFACEPT; AZATHIOPRINE; CETUXIMAB; COLCHICINE; COLLAGEN TYPE 1; CYCLOPHOSPHAMIDE; DOCETAXEL; HYDROXYCHLOROQUINE; IMATINIB; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISONE; RAPAMYCIN; RECOMBINANT RELAXIN; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DIZZINESS; DYSPNEA; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HEART PALPITATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LEUKOPENIA; LUNG FUNCTION; MALE; MIDDLE AGED; MODIFIED RODNAN SKIN SCORE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OBSERVATIONAL STUDY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RASH; REFRACTORY ACTIVE DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SKIN DISEASE; SYSTEMIC SCLEROSIS; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VOMITING; WEAKNESS; DISEASE COURSE; DRUG COMBINATION; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

ADULT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

EID: 84923174987     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140833     Document Type: Article

References (18)

1. Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, et al. Treatment of early diffuse systemic sclerosis skin disease. Clin Exp Rheumatol 2013;31 Suppl 76:166-71.
2. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012;367:2015-25.
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
4. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 2009;60:2490-8.
5. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011;70:1104-7.
6. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65:1325-9.
7. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
8. Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology 2005;44:824-6.
9. Bodemer C, Teillac D, Le Bourgeois M, Wechsler B, de Prost Y. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol 1990;123:545-6.
10. Szekanecz Z, Aleksza M, Antal-Szalmás P, Soltész P, Veres K, Szántó S, et al. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects. Clin Rheumatol 2009;28:347-50.
11. Amital H, Rewald E, Levy Y, Bar-Dayan Y, Manthorpe R, Engervall P, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003;62:175-7.
12. Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, et al. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 2007;156:1058-60.
13. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004;50:1005-7.
14. Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin-a preliminary report. Clin Rheumatol 2000;19:207-11.
15. Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977-9.
16. Kudo H, Jinnin M, Yamane K, Makino T, Kajihara I, Makino K, et al. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J Dermatol Sci 2013;69:77-80.
17. Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 2013;31 Suppl 76:151-6.
18. Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012;64:3420-9.